The USFDA had conducted the inspection from 18 March 2024 to 22 March 2024 at company's unit 1 manufacturing facility at Bonthapally, Hyderabad.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and nternational markets.
The company reported a consolidated net profit of Rs 81.39 crore in Q3 FY24, steeply higher than Rs 30.55 crore posted in Q3 FY23. Net sales jumped 45.9% year on year to Rs 392.83 crore in Q3 FY23.